Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
I'm 55 years old, perio-menopausal and was looking to lose weight
In older adults, L-carnitine also helps increase muscle mass, reduce weight and fatigue, and protects muscles from age-related degeneration [16]
As we age, decreasing adiponectin levels may worsen glucose sensitivity and lipid metabolism
supporting antimicrobial protection
Their provider recommends trying tirzepatide to push through